Novel jakinib stops the itch in teen AD
24 Mar 2021
byElvira Manzano
The oral Janus kinase (JAK) inhibitor abrocitinib, otherwise called jakinib, does well in patients 12–17 years of age with atopic dermatitis (AD) in the phase III JADE TEEN study, providing instant itch relief.